Figure 2
From: IL-18 binding protein (IL-18BP) as a novel radiation countermeasure after radiation exposure in mice
IL-18BP increased blood platelets and BM hematopoietic progenitor cells in 30-day survived mice after TBI. Mice received rhIL-18BP (1.5 mg/kg) or vehicle-injection at 48 h and 5 days after 9 Gy TBI. (a) Total white blood cells (WBC), neutrophil (NEU), lymphocyte (LYM), and platelets (PLT) were measured in whole blood samples from 30-day survived mice treated with rhIL-18BP or vehicle-injection after TBI. (b) Clonogenicity of mouse BM cells from these 30-day survived mice was also quantified in standard semisolid cultures in triplicate. CFU-GM, BFU-E and CFU-GEMM were counted 10 days later (6 mice/group). Means ± SD. Level of increase **p < 0.01; IL-18BP-treated vs. vehicle-treated. (c) HE staining of bone marrow from rhIL-18BP-treated and vehicle control-treated mice 30 days post-irradiation: longitudinal sections of entire sterna from representative mice in different groups at 20X and 40X magnification are shown; (d) Quantification of adipocytes in sternum BM sample treated with vehicle and IL-18BP 30 days post TBI are shown. Data represent mean ± SD. **p < 0.01.
